Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.12 USD | +1.78% | -11.41% | -51.53% |
05-10 | UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating | MT |
05-10 | Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.53% | 2.46B | |
+29.41% | 49.18B | |
+0.63% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.78% | 18.71B | |
+8.19% | 13.26B | |
+32.95% | 12.32B | |
-1.37% | 11.99B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Acadia Pharmaceuticals Shares Rise After Winning Summary Judgment in Nuplazid Patent Case